Efficacy and safety of first-line regimens for advanced HER2-positive breast cancer: A Bayesian network meta-analysis.

Published in: Cancer innovation (2024)

Our results suggest that the pyrotinib and trastuzumab plus docetaxel regimen is most likely to be the optimal first-line therapy for patients with HER2-positive breast cancer.

Keyphrases

positive breast cancer
systematic review
meta analyses
epidermal growth factor receptor
case control
metastatic breast cancer
squamous cell carcinoma